[1] |
YANG L, DONG XR, PENG XM, et al. Evaluation of turn around time and diagnostic accuracy of the next generation sequencing data analysis pipeline version 2 of Children's Hospital of Fudan University[J]. Chin J Evid Based Pediatr, 2018, 13(2): 118-123. DOI: 10.3969/j.issn.1673-5501.2018.02.008.
杨琳, 董欣然, 彭小敏, 等. 复旦大学附属儿科医院高通量测序数据分析流程(第二版)对遗传疾病候选变异基因筛选用时和准确性分析[J]. 中国循证儿科杂志, 2018, 13(2): 118-123. DOI: 10.3969/j.issn.1673-5501.2018.02.008
|
[2] |
QIN Q, LIU B, YANG L, et al. Application of copy number variation screening analysis process based on high-throughput sequencing technology[J]. Chin J Evid Based Pediatr, 2018, 13(4): 275-279. DOI: 10.3969/j.issn.1673-5501.2018.04.007.
秦谦, 刘博, 杨琳, 等. 基于高通量测序技术的拷贝数变异筛选分析流程的建立及应用[J]. 中国循证儿科杂志, 2018, 13(4): 275-279. DOI: 10.3969/j.issn.1673-5501.2018.04.007.
|
[3] |
KERSTEN S. Physiological regulation of lipoprotein lipase[J]. Biochim Biophys Acta, 2014, 1841(7): 919-933. DOI: 10.1016/j.bbalip.2014.03.013.
|
[4] |
OLIVECRONA G. Role of lipoprotein lipase in lipid metabolism[J]. Curr Opin Lipidol, 2016, 27(3): 233-241. DOI: 10.1097/MOL.0000000000000297.
|
[5] |
BRAHM A, HEGELE RA. Hypertriglyceridemia[J]. Nutrients, 2013, 5(3): 981-1001. DOI: 10.3390/nu5030981.
|
[6] |
DRON JS, HEGELE RA. Genetics of hypertriglyceridemia[J]. Front Endocrinol (Lausanne), 2020, 11: 455. DOI: 10.3389/fendo.2020.00455.
|
[7] |
FALKO JM. Familial chylomicronemia syndrome: A clinical guide for endocrinologists[J]. Endocr Pract, 2018, 24(8): 756-763. DOI: 10.4158/EP-2018-0157.
|
[8] |
TAKAGI A, IKEDA Y. Genetic diagnosis on hypertriglyceridemia-analysis for LPL gene mutations[J]. Nihon Rinsho, 2013, 71(9): 1569-1576.
|
[9] |
GARG A, GARG V, HEGELE RA, et al. Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 880-886. DOI: 10.1016/S2213-8587(19)30156-1.
|
[10] |
LIU LX, WU YT. Clinical advances in hypertriglyceridemia[J]. Chin J Evidence-Bases Cardiovascular Med, 2020, 12(4): 504-508. DOI: 10.3969/j.issn.1674-4055.2020.04.34.
刘立新, 武云涛. 高甘油三酯血症临床新进展[J]. 中国循证心血管医学杂志, 2020, 12(4): 504-508. DOI: 10.3969/j.issn.1674-4055.2020.04.34.
|
[11] |
CHYZHYK V, BROWN AS. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis[J]. Trends Cardiovasc Med, 2020, 30(2): 80-85. DOI: 10.1016/j.tcm.2019.03.001.
|
[12] |
GALLO A, BÉLIARD S, D'ERASMO L, et al. Familial chylomicronemia syndrome (FCS): recent data on diagnosis and treatment[J]. Curr Atheroscler Rep, 2020, 22(11): 63. DOI: 10.1007/s11883-020-00885-1.
|
[13] |
MOULIN P, DUFOUR R, AVERNA M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score"[J]. Atherosclerosis, 2018, 275: 265-272. DOI: 10.1016/j.atherosclerosis.2018.06.814.
|
[14] |
VALAIYAPATHI B, SUNIL B, ASHRAF AP. Approach to hypertriglyceridemia in the pediatric population[J]. Pediatr Rev, 2017, 38(9): 424-434. DOI: 10.1542/pir.2016-0138.
|
[15] |
CALIÒ A, BRUNELLI M, SEGALA D, et al. Angiomyolipoma of the kidney: from simple hamartoma to complex tumour[J]. Pathology, 2021, 53(1): 129-140. DOI: 10.1016/j.pathol.2020.08.008.
|
[16] |
CHENG L, GU J, EBLE JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas[J]. Am J Surg Pathol, 2001, 25(10): 1231-1236. DOI: 10.1097/00000478-200110000-00002.
|
[17] |
PFIRMANN P, COMBE C, RIGOTHIER C. Tuberous sclerosis complex: A review[J]. Rev Med Interne, 2021, 42(10): 714-721. DOI: 10.1016/j.revmed.2021.03.003.
|
[18] |
CURATOLO P, BOMBARDIERI R, JOZWIAK S. Tuberous sclerosis[J]. Lancet, 2008, 372(9639): 657-668. DOI: 10.1016/S0140-6736(08)61279-9.
|
[19] |
GILBERT B, ROUIS M, GRIGLIO S, et al. Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75% are clustered in exons 5 and 6[J]. Ann Genet, 2001, 44(1): 25-32. DOI: 10.1016/s0003-3995(01)01037-1.
|
[20] |
OKAZAKI H, GOTODA T, OGURA M, et al. Current diagnosis and management of primary chylomicronemia[J]. J Atheroscler Thromb, 2021, 28(9): 883-904. DOI: 10.5551/jat.RV17054.
|
[21] |
STEINHAGEN-THIESSEN E, STROES E, SORAN H, et al. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency[J]. Atherosclerosis, 2017, 262: 146-153. DOI: 10.1016/j.atherosclerosis.2016.08.023.
|
[22] |
WITZTUM JL, GAUDET D, FREEDMAN SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome[J]. N Engl J Med, 2019, 381(6): 531-542. DOI: 10.1056/NEJMoa1715944.
|
[23] |
ELKINS C, FRUH S, JONES L, et al. Clinical practice recommendations for pediatric dyslipidemia[J]. J Pediatr Health Care, 2019, 33(4): 494-504. DOI: 10.1016/j.pedhc.2019.02.009.
|
[24] |
CHAUDHRY R, VILJOEN A, WIERZBICKI AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome[J]. Expert Rev Clin Pharmacol, 2018, 11(6): 589-598. DOI: 10.1080/17512433.2018.1480368.
|
[25] |
MEYERS CD, TREMBLAY K, AMER A, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome[J]. Lipids Health Dis, 2015, 14: 8. DOI: 10.1186/s12944-015-0006-5.
|